Duloxetine inhibits effects of MDMA ("ecstasy") in vitro and in humans in a randomized placebo-controlled laboratory study.

PloS One
Cédric M HysekM E Liechti

Abstract

This study assessed the effects of the serotonin (5-HT) and norepinephrine (NE) transporter inhibitor duloxetine on the effects of 3,4-methylenedioxy-methamphetamine (MDMA, ecstasy) in vitro and in 16 healthy subjects. The clinical study used a double-blind, randomized, placebo-controlled, four-session, crossover design. In vitro, duloxetine blocked the release of both 5-HT and NE by MDMA or by its metabolite 3,4-methylenedioxyamphetamine from transmitter-loaded human cells expressing the 5-HT or NE transporter. In humans, duloxetine inhibited the effects of MDMA including elevations in circulating NE, increases in blood pressure and heart rate, and the subjective drug effects. Duloxetine inhibited the pharmacodynamic response to MDMA despite an increase in duloxetine-associated elevations in plasma MDMA levels. The findings confirm the important role of MDMA-induced 5-HT and NE release in the psychotropic effects of MDMA. Duloxetine may be useful in the treatment of psychostimulant dependence. Clinicaltrials.gov NCT00990067.

References

Apr 14, 1978·Science·C Van DykeR Byck
Mar 1, 1976·The British Journal of Psychiatry : the Journal of Mental Science·L R DerogatisA F Rock
Mar 1, 1992·Proceedings of the National Academy of Sciences of the United States of America·G Rudnick, S C Wall
Apr 27, 1988·European Journal of Pharmacology·G BattagliaE B De Souza
Feb 1, 1993·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·L HermleE Gouzoulis
Apr 16, 1998·European Journal of Pharmacology·M TatsumiE Richelson
Mar 25, 2000·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·M E LiechtiF X Vollenweider
May 24, 2000·Proceedings of the National Academy of Sciences of the United States of America·C SaundersA Galli
Jun 29, 2000·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·M E Liechti, F X Vollenweider
Sep 13, 2000·Quality of Life Research : an International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation·N SchmitzW Tress
Dec 26, 2001·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·F P BymasterD T Wong
Nov 13, 2003·European Journal of Pharmacology·Richard B Rothman, Michael H Baumann
Feb 25, 2005·Proceedings of the National Academy of Sciences of the United States of America·Kristopher M KahligAurelio Galli
Apr 16, 2005·The Journal of Pharmacology and Experimental Therapeutics·Christian PiflSándor Antus
Sep 25, 2007·The Journal of Pharmacology and Experimental Therapeutics·Magí FarréRafael de la Torre
Jul 16, 2008·Journal of Clinical Psychopharmacology·Erin A KolbrichMarilyn A Huestis
Dec 18, 2009·The American Journal of Drug and Alcohol Abuse·Mehmet SofuogluThomas Kosten
Jun 11, 2010·The Journal of Neuroscience : the Official Journal of the Society for Neuroscience·Heinrich J G MatthiesAurelio Galli
Sep 9, 2010·PloS One·Erich StuderusFranz X Vollenweider
Sep 16, 2010·Synapse·Richard B RothmanJohn S Partilla
Feb 2, 2011·Proceedings of the National Academy of Sciences of the United States of America·Brent J ThompsonRandy D Blakely
Mar 4, 2011·Clinical Pharmacokinetics·Mary Pat KnadlerRichard Bergstrom
Jun 17, 2011·Clinical Pharmacology and Therapeutics·C M HysekM E Liechti
Jul 1, 2011·The Journal of Clinical Endocrinology and Metabolism·Linda D SimmlerMatthias E Liechti
Oct 29, 2011·The Journal of Pharmacology and Experimental Therapeutics·Cédric M HysekMatthias E Liechti

❮ Previous
Next ❯

Citations

Nov 16, 2013·Life Sciences·Louis J De FeliceSidney S Negus
Apr 1, 2014·Social Cognitive and Affective Neuroscience·Margaret C WardleHarriet de Wit
Oct 8, 2013·Social Cognitive and Affective Neuroscience·Cédric M HysekMatthias E Liechti
Jul 17, 2013·Journal of Clinical Psychopharmacology·Cédric M HysekMatthias E Liechti
Feb 9, 2016·Progress in Neuro-psychopharmacology & Biological Psychiatry·Ralph J KoekAndrew Leuchter
Feb 9, 2016·Neuroscience and Biobehavioral Reviews·Carl Alexander RobertsCatharine Montgomery
Sep 27, 2015·Neuroscience and Biobehavioral Reviews·Philip Kamilar-Britt, Gillinder Bedi
Nov 21, 2015·Therapeutic Drug Monitoring·Elli TyrkköRobert Kronstrand
Jan 17, 2014·Journal of Clinical Pharmacology·C Michael White
Apr 20, 2016·Proceedings of the National Academy of Sciences of the United States of America·Katrin H PrellerFranz X Vollenweider
Oct 23, 2013·European Journal of Psychotraumatology·Rianne A de KleineAgnes van Minnen
Aug 27, 2016·Journal of Psychopharmacology·Anya K BershadHarriet de Wit
May 20, 2017·The International Journal of Neuropsychopharmacology·André SchmidtStefan Borgwardt
Feb 4, 2014·Biochemical Pharmacology·Linda D SimmlerMatthias E Liechti
Jan 25, 2017·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·Patrick VizeliMatthias E Liechti
Jul 24, 2014·Journal of Psychopharmacology·Yasmin SchmidMatthias E Liechti
Dec 6, 2017·The International Journal of Neuropsychopharmacology·André SchmidtStefan Borgwardt
Nov 21, 2017·Psychopharmacology·Allison A FeducciaMichael C Mithoefer
Aug 22, 2017·Scandinavian Journal of Public Health·Henrik HorwitzGesche Jürgens
Mar 25, 2014·British Journal of Pharmacology·A R GreenK C F Fone
Sep 24, 2015·Drug Metabolism and Disposition : the Biological Fate of Chemicals·Andrea E SteuerThomas Kraemer
Feb 7, 2015·The Journal of Pharmacology and Experimental Therapeutics·Yasmin SchmidMatthias E Liechti
Nov 17, 2019·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Friederike HolzeMatthias E Liechti
Feb 20, 2020·Journal of Traumatic Stress·Ingmar GormanAllison A Feduccia
Dec 13, 2019·Drug Metabolism Reviews·Kodye L AbbottSatyanarayana R Pondugula
Apr 2, 2020·Expert Opinion on Drug Metabolism & Toxicology·Esther PapaseitMagi Farré
Feb 7, 2016·Journal of Neuroendocrinology·P StrajharM E Liechti
Sep 17, 2013·British Journal of Pharmacology·Cédric M HysekMatthias E Liechti
Apr 27, 2017·Journal of Psychopharmacology·Patrick Vizeli, Matthias E Liechti
Apr 18, 2014·The Annals of Pharmacotherapy·C Michael White
Mar 15, 2015·British Journal of Pharmacology·Anna RickliMatthias E Liechti

❮ Previous
Next ❯

Methods Mentioned

BETA
MDA
scintillation proximity assay

Software Mentioned

GraphPad
HMMA
Statistica
Prism
MDA
Excel

Related Concepts

Related Feeds

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here